TraceScribeFeasibility
HFrEF Phase 3 ...

FEASIBILITY Trial Feasibility Workbench

Heart failure, reduced EF (NYHA II-IV)2 arms 1:1Global, 60 sitesTarget 1,000 randomizedOne control panel, four live consequences